Short Interest in Genfit S.A. (NASDAQ:GNFT) Grows By 10.2%

by · The Cerbat Gem

Genfit S.A. (NASDAQ:GNFT – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 74,700 shares, an increase of 10.2% from the September 30th total of 67,800 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 13,800 shares, the days-to-cover ratio is presently 5.4 days.

Genfit Stock Down 5.5 %

Shares of NASDAQ GNFT traded down $0.32 during mid-day trading on Thursday, hitting $5.53. The stock had a trading volume of 817 shares, compared to its average volume of 16,936. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The company has a 50 day moving average of $5.05 and a two-hundred day moving average of $4.47. Genfit has a twelve month low of $3.02 and a twelve month high of $6.42.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Genfit in a research note on Friday, October 11th.

Check Out Our Latest Stock Analysis on GNFT

Genfit Company Profile

(Get Free Report)

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

Further Reading